» Articles » PMID: 37285153

Analysis of Antibiotic Exposure and Development of Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

Overview
Journal JAMA Netw Open
Specialty General Medicine
Date 2023 Jun 7
PMID 37285153
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Certain antibiotic exposures have been associated with increased rates of acute graft-vs-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). Since antibiotic exposure can both affect and be affected by infections, analyzing time-dependent exposure in the presence of multiple potential confounders, including prior antibiotic exposures, poses specific analytical challenges, necessitating both a large sample size and unique approaches.

Objective: To identify antibiotics and antibiotic exposure timeframes associated with subsequent aGVHD.

Design, Setting, And Participants: This cohort study assessed allo-HCT at a single center from 2010 to 2021. Participants included all patients aged at least 18 years who underwent their first T-replete allo-HCT, with at least 6 months of follow-up. Data were analyzed from August 1 to December 15, 2022.

Exposures: Antibiotics between 7 days before and 30 days after transplant.

Main Outcomes And Measures: The primary outcome was grade II to IV aGVHD. The secondary outcome was grade III to IV aGVHD. Data were analyzed using 3 orthogonal methods: conventional Cox proportional hazard regression, marginal structural models, and machine learning.

Results: A total of 2023 patients (median [range] age, 55 [18-78] years; 1153 [57%] male) were eligible. Weeks 1 and 2 after HCT were the highest-risk intervals, with multiple antibiotic exposures associated with higher rates of subsequent aGVHD. In particular, exposure to carbapenems during weeks 1 and 2 after allo-HCT was consistently associated with increased risk of aGVHD (minimum hazard ratio [HR] among models, 2.75; 95% CI, 1.77-4.28), as was week 1 after allo-HCT exposure to combinations of penicillins with a β-lactamase inhibitor (minimum HR among models, 6.55; 95% CI, 2.35-18.20).

Conclusions And Relevance: In this cohort study of allo-HCT recipients, antibiotic choices and schedules in the early course of transplantation were associated with aGVHD rates. These findings should be considered in antibiotic stewardship programs.

Citing Articles

The Applications of Machine Learning in the Management of Patients Undergoing Stem Cell Transplantation: Are We Ready?.

Garuffo L, Leoni A, Gatta R, Bernardi S Cancers (Basel). 2025; 17(3).

PMID: 39941764 PMC: 11816169. DOI: 10.3390/cancers17030395.


Levofloxacin Prophylaxis in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation Recipients Does not Prevent Infective Complications and Infections-related Deaths.

Leardini D, Gambuti G, Muratore E, Baccelli F, Gottardi F, Venturelli F Open Forum Infect Dis. 2025; 12(2):ofae707.

PMID: 39935961 PMC: 11811901. DOI: 10.1093/ofid/ofae707.


Gut Microbiome as a Potential Marker of Hematologic Recovery Following Induction Therapy in Acute Myeloid Leukemia Patients.

Salvestrini V, Conti G, DAmico F, Cristiano G, Candela M, Cavo M Cancer Med. 2025; 14(3):e70501.

PMID: 39865898 PMC: 11770270. DOI: 10.1002/cam4.70501.


Therapeutic Drug Monitoring of Antimicrobial Drugs in Children with Cancer: A New Tool for Personalized Medicine.

Masetti R, Bossu G, Muratore E, Leardini D, Gatti M, Di Sario R Paediatr Drugs. 2024; 27(1):41-56.

PMID: 39503988 DOI: 10.1007/s40272-024-00663-5.


Pre-engraftment bacteremia after allogeneic hematopoietic cell transplantation without primary fluoroquinolone antibacterial prophylaxis.

Nguyen A, Fender J, Courjon J, Fischer A, Mappoura M, Morin S Transpl Infect Dis. 2024; 26(6):e14375.

PMID: 39312267 PMC: 11666864. DOI: 10.1111/tid.14375.


References
1.
Connelly S, Fanelli B, Hasan N, Colwell R, Kaleko M . Oral Metallo-Beta-Lactamase Protects the Gut Microbiome From Carbapenem-Mediated Damage and Reduces Propagation of Antibiotic Resistance in Pigs. Front Microbiol. 2019; 10:101. PMC: 6370672. DOI: 10.3389/fmicb.2019.00101. View

2.
Farowski F, Bucker V, Vehreschild J, Biehl L, Cruz-Aguilar R, Scheid C . Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2017; 53(1):52-57. DOI: 10.1038/bmt.2017.203. View

3.
Rashidi A, Weisdorf D . Microbiota-based approaches to mitigate infectious complications of intensive chemotherapy in patients with acute leukemia. Transl Res. 2020; 220:167-181. PMC: 7605891. DOI: 10.1016/j.trsl.2020.03.011. View

4.
Boyle N, Magaret A, Stednick Z, Morrison A, Butler-Wu S, Zerr D . Evaluating risk factors for Clostridium difficile infection in adult and pediatric hematopoietic cell transplant recipients. Antimicrob Resist Infect Control. 2015; 4:41. PMC: 4606905. DOI: 10.1186/s13756-015-0081-4. View

5.
Malard F, Vekhoff A, Lapusan S, Isnard F, Dincan-Corda E, Rey J . Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. Nat Commun. 2021; 12(1):3084. PMC: 8149453. DOI: 10.1038/s41467-021-23376-6. View